Telum Therapeutics
Telum Therapeutics develops engineered phage lytic proteins to create targeted antimicrobial therapies for drug-resistant bacterial infections. The company uses synthetic biology and AI-driven machine learning to design and optimize lytic enzymes via its proprietary APEXp® platform for improved potency, precision, and stability. Telum operates as a drug-discovery biotechnology company focused on enzybiotic therapeutics and antimicrobial development. It targets serious multidrug-resistant Gram-negative and Gram-positive infections and collaborates with healthcare and biopharma partners addressing antimicrobial resistance.
Telum Therapeutics
Telum Therapeutics develops engineered phage lytic proteins to create targeted antimicrobial therapies for drug-resistant bacterial infections. The company uses synthetic biology and AI-driven machine learning to design and optimize lytic enzymes via its proprietary APEXp® platform for improved potency, precision, and stability. Telum operates as a drug-discovery biotechnology company focused on enzybiotic therapeutics and antimicrobial development. It targets serious multidrug-resistant Gram-negative and Gram-positive infections and collaborates with healthcare and biopharma partners addressing antimicrobial resistance.